Apellis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Apellis Pharmaceuticals has a total shareholder equity of $156.3M and total debt of $454.0M, which brings its debt-to-equity ratio to 290.5%. Its total assets and total liabilities are $821.4M and $665.1M respectively.
Key information
290.48%
Debt to equity ratio
US$454.04m
Debt
| Interest coverage ratio | n/a |
| Cash | US$374.78m |
| Equity | US$156.31m |
| Total liabilities | US$665.09m |
| Total assets | US$821.39m |
Recent financial health updates
Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Jul 29
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt
Mar 14Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12Recent updates
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Aug 14Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Jul 29Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers
May 09
SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally
SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%
Apr 11Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt
Mar 14Apellis Pharmaceuticals: A Mixed Bag
Mar 05Apellis: Saved By The October Data
Dec 25There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise
Dec 15Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?
Oct 18Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion
Oct 01Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues
Sep 27Apellis: Rare Kidney Disease Data Leads To Possible First To Market
Aug 09Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?
Jul 12What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Financial Position Analysis
Short Term Liabilities: APLS's short term assets ($755.6M) exceed its short term liabilities ($200.7M).
Long Term Liabilities: APLS's short term assets ($755.6M) exceed its long term liabilities ($464.4M).
Debt to Equity History and Analysis
Debt Level: APLS's net debt to equity ratio (50.7%) is considered high.
Reducing Debt: APLS's debt to equity ratio has increased from 150.3% to 290.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable APLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: APLS is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 2.5% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/18 21:47 |
| End of Day Share Price | 2025/08/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apellis Pharmaceuticals, Inc. is covered by 35 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Michael Ulz | Baird |
| Ishan Majumdar | Baptista Research |